People who have metabolic and bariatric surgery are significantly less likely to develop psychiatric disorders compared to those who take weekly injections of GLP-1 anti-obesity medications, according to a new study presented today at the American Society for Metabolic and Bariatric Surgery (ASMBS) 2025 Annual Scientific Meeting.